Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex (1995)

No AccessJournal of UrologyCase Report1 Mar 1995Case Reports: Withdrawal Phenomenon With the Antiandrogen Casodex Peter T. Nieh, E. David Crawford, Howard I. Scher, and William K. Kelly Peter T. NiehPeter T. Nieh More articles by this author , E. David CrawfordE. David Crawford More articles by this author , Howard I. ScherHoward I. Scher More articles by this author , and William K. KellyWilliam K. Kelly More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67644-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Total androgen blockade with castration and antiandrogens has become the primary therapy in metastatic prostate carcinoma. Several reports have been published on the flutamide withdrawal syndrome with a favorable response in patients with progression of disease after lengthy remission while taking combined hormone therapy. The experience with withdrawal of the experimental nonsteroidal antiandrogen casodex * in 3 patients is reported. All patients received casodex monotherapy initially, then luteinizing hormone-releasing hormone analogues were added on progression of disease (bone scan and prostate specific antigen (PSA)) and eventually casodex was withdrawn on further progression of disease (PSA and bone scan). References 1 : Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol.1993; 149: 607. Google Scholar 2 : Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol.1993; 150: 908. Link, Google Scholar 3 : Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol.1993; 11: 1566. Google Scholar 4 : Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urol. Clin. N. Amer.1991; 18: 99. Google Scholar 5 : Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry1992; 31: 2393. Google Scholar 6 : Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate1989; 14: 103. Google Scholar 7 : Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology1994; 43: 408. Google Scholar 8 : Low androgen levels induce the development of androgen-hypersensitive cell clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl. Cancer Inst.1988; 80: 1138. Google Scholar 9 : Tamoxifen withdrawal response: report of a case. Arch. Intern. Med.1989; 149: 449. Google Scholar 10 : Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep.1979; 63: 1839. Google Scholar 11 : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med.1989; 321: 419. Google Scholar From the Department of Urology, Lahey Clinic, Burlington, Massachusetts. Division of Urology, University of Colorado, Denver, Colorado. Genitourinary Oncology Service, Division of Solid Tumor Oncology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byKOJIMA S, SUZUKI H, AKAKURA K, SHIMBO M, ICHIKAWA T and ITO H (2018) Alternative Antiandrogens to Treat Prostate Cancer Relapse After Initial Hormone TherapyJournal of Urology, VOL. 171, NO. 2, (679-683), Online publication date: 1-Feb-2004.Schellhammer P, Venner P, Haas G, Small E, Nieh P, Seabaugh D, Patterson A, Klein E, Wajsman Z, Furr B, Chen Y and Kolvenbag G (2018) Prostate Specific Antigen Decreases After Withdrawal of Antiandrogen Therapy with Bicalutamide or Flutamide in Patients Receiving Combined Androgen BlockadeJournal of Urology, VOL. 157, NO. 5, (1731-1735), Online publication date: 1-May-1997. Volume 153Issue 3SMarch 1995Page: 1070-1073 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Peter T. Nieh More articles by this author E. David Crawford More articles by this author Howard I. Scher More articles by this author William K. Kelly More articles by this author Expand All Advertisement PDF downloadLoading ...